Suppr超能文献

潜伏性结核再激活免疫炎症综合征病例的免疫特征。

Immunological characterisation of an unmasking TB-IRIS case.

机构信息

Clinical Infectious Disease Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town.

出版信息

S Afr Med J. 2012 Mar 2;102(6):512-7. doi: 10.7196/samj.5358.

Abstract

BACKGROUND

Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an early complication of combination antiretroviral therapy (cART). Two forms are recognised: (i) paradoxical - recurrent or new TB symptoms develop after cART initiation in patients receiving TB treatment prior to cART; and (ii) unmasking TB-IRIS - active TB presents within 3 months of cART in patients not receiving TB treatment at cART initiation. The latter has heightened clinical manifestations and a marked inflammatory presentation.

AIM

To gain insight into the immune pathogenesis of a case of unmasking TB-IRIS.

METHODS

The patient was recruited when starting cART and followed up at 4, 12 and 24 weeks of treatment. Peripheral blood mononuclear cells were used for flow cytometry.

RESULTS

Immunological analysis indicated increased CD4+ T-cell proportions from 1.1% at baseline to 14% at 24 weeks (the CD4 count increased from 4 cells/µl at baseline to 41 cells/µl at 24 weeks). HIV viral load fell from 460 774 to 1 405 copies/ml during the same period. The proportion of TB antigen (PPD)-specific CD4+IFN-γ+ cells increased from 0.4% at baseline and 4 weeks (IRIS onset) to 7.8% at 12 weeks (after resolution of the IRIS episode); this fell to 0.7% at 24 weeks. The surface phenotype of CD4+IFN-γ+ cells during the episode was CD45RO+, CD45RA-, CCR7-, CD62L-, CCR5+/- and CD69-. We found a distorted balance between central memory and effector memory T-cells at cART commencement that might have predisposed the patient to unmasking TB-IRIS. We showed that this might have reflected compromised thymic output. Discussion. While it has been suggested that tuberculin-specific Th1-responses induce TB-IRIS in HIV co-infected patients, our data in this case indicated that these cells were expanded only after IRIS onset and were therefore not inducing TB-IRIS.

CONCLUSION

We describe, in hitherto unpublished detail, the immunological characterisation of an unmasking TB-IRIS case; we show that thymic output may be compromised at IRIS onset.

摘要

背景

结核病相关免疫重建炎症综合征(TB-IRIS)是联合抗逆转录病毒治疗(cART)的早期并发症。有两种形式:(i)矛盾性 - 在接受 cART 治疗前接受结核病治疗的患者在开始 cART 后出现复发或新的结核病症状;和(ii)潜伏性结核病-IRIS - 在开始 cART 时未接受结核病治疗的患者在 cART 后 3 个月内出现活动性结核病。后者具有更高的临床表现和明显的炎症表现。

目的

深入了解潜伏性结核病-IRIS 病例的免疫发病机制。

方法

在开始 cART 时招募患者,并在治疗的第 4、12 和 24 周进行随访。使用外周血单核细胞进行流式细胞术分析。

结果

免疫分析表明,CD4+T 细胞比例从基线时的 1.1%增加到 24 周时的 14%(CD4 计数从基线时的 4 个/µl 增加到 24 周时的 41 个/µl)。同期 HIV 病毒载量从 460774 降至 1405 拷贝/ml。PPD-特异性 CD4+IFN-γ+细胞的比例从基线时的 0.4%和 4 周(IRIS 发作)增加到 12 周(IRIS 发作后)的 7.8%;到 24 周时降至 0.7%。IRIS 发作期间 CD4+IFN-γ+细胞的表面表型为 CD45RO+、CD45RA-、CCR7-、CD62L-、CCR5+/-和 CD69-。我们发现,在开始 cART 时,中央记忆和效应记忆 T 细胞之间存在不平衡,这可能使患者容易发生潜伏性结核病-IRIS。我们表明,这可能反映了胸腺输出受损。讨论。虽然有人提出结核菌素特异性 Th1 反应会诱导 HIV 合并感染患者发生结核病-IRIS,但我们在本病例中的数据表明,这些细胞仅在 IRIS 发作后才被扩增,因此不会诱导结核病-IRIS。

结论

我们详细描述了一例潜伏性结核病-IRIS 病例的免疫学特征;我们表明,在 IRIS 发作时,胸腺输出可能会受到损害。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验